Display options
Share it on

Trends Endocrinol Metab. 1997 Apr;8(3):89-92. doi: 10.1016/s1043-2760(97)00015-5.

Salmon calcitonin in the prevention and treatment of osteoporosis.

Trends in endocrinology and metabolism: TEM

L V Avioli

Affiliations

  1. Division of Bone and Mineral Diseases, Washington University School of Medicine, St. Louis, MO 63110USA.

PMID: 18406791 DOI: 10.1016/s1043-2760(97)00015-5

Abstract

The principal calcitonins used therapeutically are porcine, human (synthetic), salmon (synthetic), and eel. Of these substances, salmon calcitonin is the most potent (Reginster 1991). Injectable forms of salmon calcitonin were first indicated for use in the treatment of Paget's disease in the United States and later received an indication for use in the treatment of postmenopausal osteoporosis. The injectable [intramuscular (IM) or subcutaneous (SC)] formulation of salmon calcitonin, however, has been associated with a high rate of noncompliance in elderly patients. The recently approved nasal-spray formulation has ameliorated the difficulties inherent in parenteral administration and is considered a suitable option as an alternative therapy in patients who are not appropriate candidates for estrogen replacement therapy. (Trends Endocrinol Metab 1997;8:89-92). (c) 1997, Elsevier Science Inc.

Publication Types